NBE-Therapeutics, a private Basel based clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform, was acquired by Boehringer Ingelheim. The total transaction value is 1.18 billion euros and also includes contingent clinical and regulatory milestones. The consummation of the transaction is subject to customary closing conditions and is expected during the course of Q1 2021.
The team
Walder Wyss advises Boehringer Ingelheim. The team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital – pictured left) and Robert von Rosen (Partner, Corporate/M&A and Venture Capital) and included Robert Desax (Partner, Tax), Jessica Aeschbach Flórez (Senior Associate, Corporate/M&A), Karina Tschon (Associate, Corporate/M&A and Venture Capital), Flurin Vionnet-Riederer (Associate, Corporate/M&A), Christoph Burckhardt (Associate, Corporate/M&A) and Jonas Knechtli (Senior Associate, Employment).
VISCHER advised NBE-Therapeutics and its shareholders in this transaction. The team was led by Matthias Staehelin (pictured right) with Vincent Reardon, Pauline Pfirter, Céderic Saladin (all Corporate) and Nadia Tarolli (Tax).
